EyePoint Pharmaceuticals | 4:持股变动声明-董事 GUYER DAVID R
EyePoint Pharmaceuticals | 4:持股变动声明-高管 Elston George
EyePoint Pharmaceuticals | 8-K:重大事件
EyePoint Pharmaceuticals | 4:持股变动声明-董事 GUYER DAVID R
EyePoint Pharmaceuticals | 144:拟议出售证券
EyePoint Pharmaceuticals | 10-Q:季度报表
EyePoint Pharmaceuticals | 4:持股变动声明-股东 Cormorant Asset Management, LP
EyePoint Pharmaceuticals | 8-K:EyePoint Pharmicals公布2024年第一季度财务业绩并重点介绍最近的公司发展
EyePoint Pharmaceuticals | 8-K:重大事件
EyePoint Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-Adage Capital Management, L.P.(9.90%),Robert Atchinson(9.90%)等
EyePoint Pharmaceuticals | SC 13G:超过5%持股股东披露文件-Adage Capital Management, L.P.(10.35%),Robert Atchinson(10.35%)等
EyePoint Pharmaceuticals | DEFA14A:其他
EyePoint Pharmaceuticals | DEF 14A:股东委托书决议
EyePoint Pharmaceuticals | 3:首次持股声明-股东 Adage Capital Management, L.P.
EyePoint Pharmaceuticals | 4:持股变动声明-股东 Cormorant Asset Management, LP
EyePoint Pharmaceuticals | 4:持股变动声明-高管 Paggiarino Dario A.
EyePoint Pharmaceuticals | 10-K:年度报表
EyePoint Pharmaceuticals | 8-K:EyePoint Pharmaceuticals公布了2023年第四季度和全年财务业绩,并重点介绍了最近的公司发展
EyePoint Pharmaceuticals | 4:持股变动声明-高管 Ribeiro Ramiro
EyePoint Pharmaceuticals | 3:首次持股声明-高管 Ribeiro Ramiro
暂无数据